The Human Parechovirus Qualitative PCR Test is a diagnostic tool designed to detect the presence of human parechovirus (HPeV) in a patient's sample, typically collected from the throat, stool, or cerebrospinal fluid. This virus is a member of the Picornaviridae family and can cause a range of illnesses, from mild gastrointestinal and respiratory infections to severe conditions like sepsis and meningitis, particularly in infants and young children.
The test employs Polymerase Chain Reaction (PCR) technology, a highly sensitive and specific method that amplifies segments of the virus's DNA to detectable levels. This allows for the rapid and accurate identification of the virus, facilitating timely intervention and management of the infection.
Performed at DNA Labs UAE, a state-of-the-art facility known for its advanced diagnostic services, the Human Parechovirus Qualitative PCR Test is priced at 1000 AED. The cost reflects the sophisticated nature of the testing process and the expertise required to conduct it. By choosing DNA Labs UAE for this test, patients can expect reliable results, which are crucial for the effective treatment and management of infections caused by the human parechovirus.
The Immunohistochemistry Digital Breast Cancer Panel 3 Test is a sophisticated diagnostic tool used to aid in the detection and characterization of breast cancer. This test is performed at DNA Labs UAE, a reputable facility known for its cutting-edge technology and expert medical staff. Priced at 1000 AED, this test utilizes immunohistochemistry (IHC) techniques to identify specific proteins and markers on the surface of cells in breast tissue samples. These markers can provide valuable information about the type of breast cancer, its aggressiveness, and potential response to treatment. By employing digital imaging technology, the test ensures highly accurate and detailed analysis, enabling personalized treatment plans for patients. This test is essential for oncologists and patients alike, offering insights that can significantly impact treatment decisions and outcomes.
The Immunohistochemistry Bladder vs Prostate Carcinoma Panel Test is a sophisticated diagnostic tool used to distinguish between bladder cancer and prostate carcinoma. This panel test employs immunohistochemistry (IHC) techniques, which involve the use of antibodies to detect specific antigens in tissue samples, thereby helping in the accurate identification of the type of cancer present. The differentiation between bladder and prostate carcinoma is crucial for determining the appropriate treatment path and prognosis.
Performed at DNA Labs UAE, a leading facility in medical diagnostics, this test is priced at 1170 AED. DNA Labs UAE is renowned for its state-of-the-art technology and expert team, ensuring high-quality and reliable test results. The test is conducted by experienced professionals who specialize in cancer diagnostics, offering patients and healthcare providers critical insights into the nature of the carcinoma, thereby facilitating targeted therapy options and improved patient care.
The Immunohistochemistry Germ Cell Tumour Panel Test is a specialized diagnostic procedure aimed at identifying germ cell tumors through the detection of specific markers present in these types of cancers. Utilizing immunohistochemistry (IHC), this test employs antibodies to target and bind to antigens in the cells of a tissue section, which can then be visualized under a microscope. This method is crucial for the accurate diagnosis and classification of germ cell tumors, which can originate in the ovaries or testes, but may also be found in other areas of the body due to migratory embryonic germ cells.
Performed at DNA Labs UAE, a leading facility in medical diagnostics, this test is priced at 1170 AED. The laboratory is equipped with state-of-the-art technology and staffed by experienced professionals to ensure reliable and precise results. The Immunohistochemistry Germ Cell Tumour Panel Test is essential for guiding the treatment plan and prognosis for patients with suspected germ cell tumors, providing vital information on the tumor type and its potential behavior.
The Immunohistochemistry Neuroendocrine Tumor Panel Test is a specialized diagnostic tool used to identify and characterize neuroendocrine tumors (NETs) through the detection of specific markers present in these types of cells. This test utilizes antibodies to target and bind to antigens in the tissues obtained from a patient, providing crucial information about the type, grade, and potential behavior of the tumor. It is an essential component in the management of patients with neuroendocrine tumors, aiding in accurate diagnosis, prognosis, and guiding treatment strategies.
Performed at DNA Labs UAE, a leading facility in medical diagnostics, the test ensures high-quality analysis and reliable results. The cost of the Immunohistochemistry Neuroendocrine Tumor Panel Test is 1170 AED, reflecting the intricate and detailed process involved in detecting the presence and extent of neuroendocrine tumors. This test is particularly valuable for healthcare professionals in making informed decisions about patient care, offering a path towards tailored treatment plans for individuals diagnosed with NETs.
The Immunohistochemistry PD-1 Test is a specialized diagnostic procedure used to detect the presence of the Programmed Death-1 (PD-1) protein in tissue samples. PD-1 is a checkpoint protein on T cells that, when engaged, can inhibit the immune response, including the immune system's ability to attack cancer cells. This test is particularly relevant in the context of cancer diagnosis and treatment, as it helps in identifying patients who may benefit from immunotherapy treatments targeting the PD-1 pathway.
Performed at DNA Labs UAE, a leading laboratory known for its advanced diagnostic solutions, the test involves staining tissue samples with specific antibodies that bind to the PD-1 protein. This allows pathologists to visually assess the presence and distribution of PD-1 expressing cells under a microscope. The results from this test can provide valuable information for guiding treatment decisions, especially in the management of various cancers such as melanoma, lung cancer, and more.
The cost of the Immunohistochemistry PD-1 Test at DNA Labs UAE is 1170 AED. This price reflects the specialized nature of the test, including the use of advanced immunohistochemistry techniques and the expertise required to accurately interpret the results. Patients and healthcare providers looking to utilize this test should consider it an investment in personalized cancer care, potentially leading to more targeted and effective treatment strategies.
The PML RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative MRD Monitor Test is a specialized diagnostic tool used to detect and quantify the specific chromosomal abnormality associated with Acute Promyelocytic Leukemia (APL), a subtype of acute myeloid leukemia. This test identifies the presence of the PML-RARA fusion gene, which results from the translocation between chromosomes 15 and 17, denoted as t(15;17)(q22;q12). This genetic anomaly is a hallmark of APL and plays a crucial role in the disease's pathogenesis.
The test is highly sensitive and is utilized not only for diagnosing APL but also for monitoring minimal residual disease (MRD) during and after treatment. The ability to quantitatively measure the levels of the PML-RARA gene rearrangement allows healthcare providers to assess the effectiveness of therapy, detect early signs of relapse, and make informed decisions regarding patient management.
Performed at DNA Labs UAE, the test is offered at a cost of 1220 AED. This state-of-the-art facility ensures accurate and reliable results, employing advanced molecular techniques to support the precise diagnosis and monitoring of patients with APL. The quantitative aspect of this test is particularly valuable for tailoring patient-specific treatment plans and improving the overall prognosis by enabling timely interventions.
The PML RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative PCR Test is a sophisticated diagnostic assay performed at DNA Labs UAE, designed to detect the specific chromosomal abnormality t(15;17)(q22;q12). This rearrangement results in the fusion of the PML gene on chromosome 15 with the RARA gene on chromosome 17, a hallmark of Acute Promyelocytic Leukemia (APL), a subtype of acute myeloid leukemia. The test employs quantitative Polymerase Chain Reaction (PCR) techniques to precisely measure the levels of the PML-RARA fusion gene, which is critical for diagnosing APL, monitoring treatment response, and detecting minimal residual disease (MRD) in patients.
With a cost of 1220 AED, the test is an essential tool in the personalized management of patients with APL, offering rapid and sensitive detection of the PML-RARA rearrangement. This information is invaluable for clinicians in guiding treatment decisions, including the use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which specifically target cells expressing the PML-RARA fusion protein. By quantifying the presence of the fusion gene, the test not only confirms the diagnosis but also helps in predicting patient prognosis and in the early detection of relapse, making it a cornerstone in the management of Acute Promyelocytic Leukemia.
The Tacrolimus Genotyping CYP3A5 Test is a specialized genetic test performed to determine how an individual metabolizes tacrolimus, a critical immunosuppressive medication commonly used in organ transplant patients to prevent rejection. This test specifically analyzes the CYP3A5 gene, which plays a significant role in the enzyme production that metabolizes tacrolimus and other drugs. Understanding a patient's CYP3A5 genotype can help healthcare providers tailor drug dosages to achieve optimal therapeutic levels, reducing the risk of drug toxicity or treatment failure.
This precise and valuable test is available at DNA Labs UAE, a leading provider of genetic testing services in the United Arab Emirates. The test is priced at 1220 AED, offering patients and healthcare professionals a critical tool in the management of transplant medications and the customization of treatment plans based on genetic makeup. By leveraging such genetic insights, DNA Labs UAE supports more effective and personalized medical care, particularly for those undergoing organ transplantation.
The TPMT (Thiopurine Methyltransferase) Genotyping Test is a critical diagnostic tool designed to assess an individual's genetic predisposition to metabolize thiopurine medications. These medications are commonly prescribed for treating certain autoimmune diseases and leukemias. The TPMT enzyme plays a significant role in the metabolism of these drugs, and variations in the TPMT gene can lead to differences in how individuals process these medications. This can affect both the efficacy and toxicity of the treatment.
By analyzing specific genetic markers, the TPMT Genotyping Test can predict the patient's enzyme activity level, helping healthcare providers to tailor drug dosages to the patient's genetic profile. This personalized approach aims to maximize therapeutic benefits while minimizing adverse effects, ensuring a safer and more effective treatment plan.
In the United Arab Emirates, this valuable test is available at DNA Labs UAE, a leading facility in genetic diagnostics. The cost of the TPMT Genotyping Test at DNA Labs UAE is 1220 AED. Opting for this test can be a crucial step for patients who are about to start thiopurine therapy, offering them a customized healthcare solution based on their genetic makeup.
